Facilitated stent delivery using applied topical lubrication.

OBJECTIVES: The goal of this study was to assess the utility of topical lubrication to aid stent delivery in challenging anatomy and its effects on long-term clinical outcome. BACKGROUND: Failed stent delivery is encountered in up to 5% of percutaneous coronary interventions (PCI). METHODS: The effectiveness of topically applied lubrication to facilitate stent delivery after failed stent placement was evaluated in 20 (2.5%) out of 813 consecutive patients undergoing PCI. Initial attempts at stent delivery failed despite balloon predilatation and use of moderate-to-stiff guidewires in all patients. The lubricious solution used was Rotaglide, a phospholipid emulsion originally designed to reduce catheter friction during rotational atherectomy. Following unsuccessful delivery, stents were removed from the guiding catheters, topically saturated with Rotaglide, and deployment immediately reattempted. Procedural efficacy and long-term clinical outcomes were assessed. RESULTS: The study population included 20 patients aged 69 +/- 10 years, all of whom had complex lesions (ACC/AHA Class B(2) or C). Rotaglide lubricated stents were successfully deployed at the target lesions in 17 of the 20 patients (85%). Patients were followed 19.5 +/- 3.2 months after their index procedure. There were no periprocedural complications or subacute stent thromboses. Of the 14 patients with drug-eluting stents, none had clinical restenosis or target vessel revascularization. Target lesion revascularization secondary to restenosis was required in 1 of 3 patients treated with bare-metal stents. CONCLUSIONS: Topical lubrication is a simple and effective aid for stent delivery in complex lesions. Rotaglide appears safe and biocompatible with drug-eluting stents.

Efficacy of intracoronary nicardipine in the treatment of no-reflow during percutaneous coronary intervention.

OBJECTIVES: The goal of this study was to evaluate the safety and efficacy of nicardipine in reversing no-reflow during percutaneous coronary intervention (PCI). BACKGROUND: No-reflow is a common complication of PCI in patients with acute coronary syndromes or venous bypass graft disease. Although nicardipine has an attractive pharmacological profile and has been used clinically to treat no-reflow, there is a paucity of published data regarding its effectiveness in this setting. METHODS: We conducted a retrospective analysis of 72 consecutive patients who received intracoronary nicardipine to reverse no-reflow during coronary intervention. Qualitative TIMI flow grade and quantitative TIMI frame count methods were used to assess the efficacy of nicardipine. RESULTS: A mean of 460 +/- 360 mcg of intracoronary nicardipine was used. No-reflow was successfully reversed with complete restoration of TIMI 3 flow in 71 of 72 patients (98.6%). TIMI flow grade improved from 1.65 +/- 0.53 prior to nicardipine to 2.97 +/- 0.24 after treatment (P < 0.001). TIMI frame count decreased from 57 +/- 40 at the time of no-reflow to 15 +/- 12 after nicardipine administration (P < 0.001). Nicardipine therapy was well tolerated without adverse hemodynamic or chronotropic effects. CONCLUSIONS: In this largest series to date, intracoronary nicardipine was demonstrated to be a safe and highly effective pharmacological agent to reverse no-reflow during PCI.